AI Analysis
Log in to generate an AI summary for this stock.
Log in to generate a MOAT report for this stock.
Log in to generate an earnings report for this stock.
Log in to generate an operating leverage report for this stock.
Log in to generate a management report for this stock.
Log in to generate a valuation report for this stock.
Senti Biosciences, Inc.
Video analysis: SNTI
All videosNo video analysis for this stock yet. Request one from our team.
News: SNTI
Senti Biosciences (SNTI) to Announce Quarterly Earnings on Thursday
Senti Biosciences (NASDAQ: SNTI - Get Free Report) will likely be issuing its Q2 2026 results before the market opens on Thursday, August 6th. Analysts expect the company to post earnings of ($0.33) per share and revenue of $0.0150 million for the quarter. Individuals are encouraged to explore the company's upcoming Q2 2026 earning summary page
Senti Biosciences Holdings, Inc. Announces a Strategic Transaction to Unlock Value for its Gene-Circuit-Enabled Pipeline, Including SENTI-202, and to Sharpen its Focus on Next-Generation Controllable Genetic Medicines Powered by its Regulator Dial™ Technology Platform
SOUTH SAN FRANCISCO, Calif., July 15, 2026 (GLOBE NEWSWIRE) -- Senti Biosciences Holdings, Inc. (NASDAQ: SNTI) (“SBH” or the “Company”) today announced a strategic transaction designed to sharpen its focus on next-generation controllable genetic medicines powered by its Regulator Dial™ technology platform (the “Retained Assets”) and unlock value for its Gene-Circuit-enabled pipeline, including SENTI-202, currently being advanced by its wholly owned subsidiary, Senti Biosciences, Inc.
Similar companies
-
Karyopharm Therapeutics Inc.
KPTI
·
NASDAQ
Compare
-
X4 Pharmaceuticals, Inc.
XFOR
·
NASDAQ
Compare
-
Century Therapeutics, Inc.
IPSC
·
NASDAQ
Compare
-
Barinthus Biotherapeutics plc
BRNS
·
NASDAQ
Compare
-
CEL-SCI Corporation
CVM
·
New York Stock Exchange Arca
Compare
-
Cue Biopharma, Inc.
CUE
·
NASDAQ
Compare